ORCHESTRA BIOMED HOLDI

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

12 Nov 2024 15:12:39 By Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 Aug 2024 15:20:20 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

04 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

22 May 2024 07:43:18 By Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

13 May 2024 15:58:13 By Nasdaq GlobeNewswire

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

27 Mar 2024 15:17:23 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Upcoming Investor Conferences

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

06 Mar 2024 07:37:17 By Nasdaq GlobeNewswire

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

08 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

13 Nov 2023 15:21:38 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

09 Nov 2023 15:42:43 By Nasdaq GlobeNewswire

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

19 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 15:34:21 By Nasdaq GlobeNewswire